Semaglutide and liraglutide are both GLP-1 receptor agonists from the same maker, and liraglutide is effectively semaglutide's predecessor. They share a mechanism — mimicking the gut hormone GLP-1 to curb appetite and improve glucose control — but differ in two practical ways that matter a lot: dosing frequency and potency. Liraglutide is a daily injection with more modest weight loss; semaglutide is once weekly and, in trials, produces roughly double the average weight reduction.
At a glance
| Semaglutide | Liraglutide | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brand names | Ozempic, Wegovy, Rybelsus | Victoza, Saxenda |
| FDA status | Approved | Approved |
| Dosing frequency | Once weekly (or daily oral Rybelsus) | Once daily injection |
| Typical trial weight loss | ~15% of body weight | ~6–8% of body weight |
| Generation | Newer, longer-acting | Earlier-generation GLP-1 |
| Main side effects | GI: nausea, diarrhea, constipation | GI: nausea, diarrhea, constipation |
The bottom line
Bottom line: Semaglutide is the more potent, more convenient successor — once weekly instead of daily, with roughly double the average weight loss in trials. Liraglutide remains a valid, well-established option and its shorter action can be an advantage in some clinical situations. Both are prescription GLP-1 medicines with the same side-effect profile.
Frequently asked questions
Is semaglutide more effective than liraglutide?
In trials semaglutide produced roughly double the average weight loss of liraglutide (~15% vs ~6–8%) and is dosed once weekly rather than daily. Liraglutide is still an effective, approved option.
Why is liraglutide taken daily but semaglutide weekly?
Semaglutide was engineered for a much longer half-life, allowing once-weekly dosing, whereas liraglutide's shorter duration requires daily injection. Semaglutide also has a daily oral form (Rybelsus).
Are semaglutide and liraglutide made by the same company?
Yes — both are GLP-1 receptor agonists from the same manufacturer, with liraglutide being the earlier-generation drug that preceded semaglutide.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Peer-reviewed study
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. Peer-reviewed study
- Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023. Peer-reviewed study
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. Peer-reviewed study
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. Peer-reviewed study
- Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022. Peer-reviewed study
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015. Peer-reviewed study
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016. Peer-reviewed study
- Guo T, Yan W, Cui X, et al. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Mol Med. 2023. Peer-reviewed study
- Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014. Peer-reviewed study
- Ni XY, Feng XJ, Wang ZH, et al. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta Pharmacol Sin. 2024. Peer-reviewed study
- Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020. Peer-reviewed study